ANXA1 and glioblastoma: Moreover, based on the operative specimens from five GBM patients (MGH26, MGH28, MGH29, MGH30, and MGH31), ANXA1 may promote metastasis (R = 0.21, p < 0.001) and inflammation (R = 0.21, p < 0.001) in GBM, which may lead to a poor prognosis in GBM patients.